RARE Stock Summary

• RARE's price/sales ratio is 33.43; that's higher than the P/S ratio of 96.58% of US stocks.
• Equity multiplier, or assets relative to shareholders' equity, comes in at 1.16 for Ultragenyx Pharmaceutical Inc; that's greater than it is for only 10.02% of US stocks.
• Revenue growth over the past 12 months for Ultragenyx Pharmaceutical Inc comes in at 169.7%, a number that bests 96.59% of the US stocks we're tracking.
• Stocks that are quantitatively similar to RARE, based on their financial statements, market capitalization, and price volatility, are CMRX, ARVN, TBPH, CUE, and SRRK.
• RARE's SEC filings can be seen here. And to visit Ultragenyx Pharmaceutical Inc's official web site, go to www.ultragenyx.com.